Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674950 | 0.89 | POLB (0.34) | ALDH1A1POLBTSHRRXRARXRB | |
| SCHEMBL3073700 | 0.85 | GAA (0.35) | ALDH1A1TSHRRXRASMN1; SMN2HTT | |
| SCHEMBL3074996 | 0.84 | PTGDR2 (0.44) | POLBTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3085602 | 0.83 | ALDH1A1 (0.36) | ALDH1A1POLBTSHRRXRAMEN1 | |
| SCHEMBL3078835 | 0.81 | TSHR (0.53) | ALDH1A1TSHRRXRAMEN1KMT2A | |
| SCHEMBL3085581 | 0.81 | RARB (0.35) | ALDH1A1POLBTSHRRXRAMEN1 | |
| SCHEMBL3468200 | 0.80 | ESR1 (0.34) | ALDH1A1RXRARXRBRXRGSMN1; SMN2 | |
| SCHEMBL3085880 | 0.79 | NPC1 (0.33) | RXRARXRBRXRGSMN1; SMN2 | |
| SCHEMBL3078288 | 0.78 | APOBEC3A (0.39) | ALDH1A1POLBTSHRRXRAMEN1 | |
| SCHEMBL14098920 | 0.78 | NPC1 (0.34) | RXRARXRBRXRGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | claimed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | claimed |
| EP-1891026-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Smithkline Beecham Corporation (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006127871-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | claimed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| EP-1891026-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Smithkline Beecham Corporation (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006127871-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ALDH1A1 928/4885POLB 3422/4885TSHR 227/4885 |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ALDH1A1 928/4885POLB 3422/4885TSHR 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.